The expansion of LENTIVERSE (TM) platform introduces "One Lentiviral Vector Platform, Two Paths to Advance Cures," aligning scientific rigor with transparent economics and global accessibility.
There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector ...
SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of lentiviral vector-transduced autologous hematopoietic stem cells (HSCs) increased ...
Lentiviral vectors have emerged as indispensable tools in gene therapy, offering the ability to integrate therapeutic genes into both dividing and non-dividing cells. Their unique capacity to achieve ...
Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. To meet patient needs, reliable and cost-effective ...
LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell” or the “Company”), a specialist viral vector Contract Development and Manufacturing Organisation (“CDMO”) for cell and gene therapy ...
AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...
VENLO, the Netherlands--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR ...
The β 2 common integrin subunit CD18 is essential for leukocyte–endothelial adhesion and extravasation to inflamed or infected tissue. Damaging variants in ITGB2 ...
Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next. Click for my GNTA update.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback